Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's

Executive Summary

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

You may also be interested in...



Unthinkable? Reports That AZ May Spin Off China Ops Amid Geopolitical Risks

AstraZeneca is reportedly considering joining a prominent investment fund to spin off and list its Chinese entities, in an apparent bid to better insulate them against potential geopolitical risks.

Samsung Biologics Strikes $400m+ Biosimilars Supply Deal With Pfizer

Samsung Biologics has struck a deal worth over $400m to manufacture multiple biosimilars for Pfizer.

Indoco Builds On Recent Growth With Acquisition In US

Indoco says it has marked a major milestone with a $4m deal to take a controlling stake in US firm Florida Pharmaceutical Products, strengthening the Indian company’s position in the US market.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel